D. Western Therapeutics Institute, Inc.

Equities

4576

JP3548740004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 10/05/2024 BST			5-day change	1st Jan Change
105 ^JPY	-1.87%		-4.55%	-25.53%

02-14	D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	CI
2023	D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	CI

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

November 11, 2022 at 06:30 am

D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the year ending December 31, 2022. For the year ending December 31, 2022, the company expects net sales of JPY 370 million, operating loss of JPY 690 million and loss attributable to owners of parent of JPY 670 million or JPY 22.82 per share.

Latest news about D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	02-13	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	09/08/23	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	15/05/23	CI
D. Western Therapeutics Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	14/02/23	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	11/11/22	CI
D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.	18/07/22	CI
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥901.216203 million in funding from Whiz Partners Inc.	19/06/22	CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022	13/05/22	CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022	14/02/22	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	12/11/21	CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021	11/08/21	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	11/08/21	CI
UBiENCE Inc. announced that it expects to receive ¥100 million in funding from D. Western Therapeutics Institute, Inc.	16/06/21	CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2021	12/05/21	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	12/05/21	CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2020	11/02/21	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	11/02/21	CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	13/11/20	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2020	13/11/20	CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Sis Months Ended June 30, 2020	14/08/20	CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2020	14/08/20	CI
D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm	06/08/20	CI
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm	21/07/20	CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Earnings Guidance for the Full Year Ending December 31, 2020	15/05/20	CI

Chart D. Western Therapeutics Institute, Inc.

Duration

Period

Chart D. Western Therapeutics Institute, Inc.

More charts

Company Profile

D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.

Sector

Biotechnology & Medical Research

Calendar

12/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
D. WESTERN THERAPEUTICS INSTITUTE, INC.	-25.53%	21.74M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs